October 1 - 2, 2015    Boston MA , Stati Uniti
Recent changes in the healthcare system have put a greater focus on the development and availability of generic drugs. The pharmaceutical industry has responded by exploring alternative delivery methods, creating new test designs and, most notably, developing the first American biosimilar. These advances have been met with acclaim, but they do bring new challenges. Regulatory ambiguity in testing procedures delay generic developers, and legal action from originator drug companies restricts those focusing on biosimilars. This summit will further explore the scientific necessity of this subject, while guiding experts through their collective difficulties.


Location: Hilton Boston Back Bay
Contatta 40 Dalton St. Boston , USA


ExL Events, Inc.
494 8th Ave, 4th Floor New York, NY 10001

Eventi correlati

Bioequivalence Summit September 26 - 27, 2016
Bioequivalence Summit October 1 - 2, 2015